This 2005 review by Liu et al. explores the potential of nanoparticle-conjugated chelators as a novel therapeutic strategy for Alzheimer’s disease (AD). Traditional chelation therapies, such as desferrioxamine, have shown limited efficacy due to poor blood-brain barrier (BBB) permeability and systemic side effects. The authors propose that nanoparticles conjugated to
This review provides a detailed examination of the biological mechanisms and technological platforms underlying vaccine adjuvants. Adjuvants are classified into immunostimulatory agents and delivery systems, both of which enhance vaccine efficacy by activating innate immunity and optimizing antigen presentation. Key mechanisms include engagement of pattern recognition receptors such as Toll-like
This review article explores the role of glutathione (GSH) in neurodegenerative diseases such as Parkinson’s and Alzheimer’s, focusing on the challenges of delivering GSH to the central nervous system due to its low stability and poor bioavailability. It highlights the potential of innovative GSH delivery systems—including prodrugs, nanoparticles, and liposomal
This study explores the use of methylene blue (MB)-loaded nanoparticles for treating Alzheimer’s disease (AD) and other tauopathies. The nanoparticles, designed to improve MB’s bioavailability in the brain, are formulated using PLGA-b-PEG and are 136.5 nm in size. They exhibit a sustained drug release profile, effectively reducing tau protein levels
